BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 9874784)

  • 1. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
    Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
    Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
    Reszka AA; Halasy-Nagy JM; Masarachia PJ; Rodan GA
    J Biol Chem; 1999 Dec; 274(49):34967-73. PubMed ID: 10574973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
    Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
    Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro.
    Töyräs A; Ollikainen J; Taskinen M; Mönkkönen J
    Eur J Pharm Sci; 2003 Jul; 19(4):223-30. PubMed ID: 12885386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells.
    Crick DC; Andres DA; Danesi R; Macchia M; Waechter CJ
    J Neurochem; 1998 Jun; 70(6):2397-405. PubMed ID: 9603204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells.
    Bassa BV; Roh DD; Vaziri ND; Kirschenbaum MA; Kamanna VS
    Biochim Biophys Acta; 1999 Mar; 1449(2):137-49. PubMed ID: 10082972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
    Woo JT; Kasai S; Stern PH; Nagai K
    J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
    Frith JC; Rogers MJ
    J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation.
    Fernández-Hernando C; Suárez Y; Lasunción MA
    Mol Cell Neurosci; 2005 Aug; 29(4):591-602. PubMed ID: 15951198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.
    Benford HL; Frith JC; Auriola S; Mönkkönen J; Rogers MJ
    Mol Pharmacol; 1999 Jul; 56(1):131-40. PubMed ID: 10385693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.
    Reszka AA; Halasy-Nagy J; Rodan GA
    Mol Pharmacol; 2001 Feb; 59(2):193-202. PubMed ID: 11160853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
    Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
    J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome.
    Frenkel J; Rijkers GT; Mandey SH; Buurman SW; Houten SM; Wanders RJ; Waterham HR; Kuis W
    Arthritis Rheum; 2002 Oct; 46(10):2794-803. PubMed ID: 12384940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
    Frith JC; Mönkkönen J; Auriola S; Mönkkönen H; Rogers MJ
    Arthritis Rheum; 2001 Sep; 44(9):2201-10. PubMed ID: 11592386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.